Search
Results: 12
Crystallisation and physicochemical property characterisation of conformationally-locked co-crystals of fenamic acid derivatives
Kate Wittering, Lauren Agnew, Anneke R Klapwijk, Karen Robertson, Alexander Cousen, Dyanne Cruickshank, Chick Wilson
May 21, 2015
Polymorphism in drug compounds can cause significant problems for industrial-scale production and so a method for restricting the conformational freedom of the target compound whilst retaining desired chemical properties is...
Crystallisation and physicochemical property characterisation of conformationally-locked co-crystals of fenamic acid derivatives
Kate Wittering, Lauren Agnew, Anneke R Klapwijk, Karen Robertson, Alexander Cousen, Dyanne Cruickshank, Chick Wilson
May 21, 2015
Polymorphism in drug compounds can cause significant problems for industrial-scale production and so a method for restricting the conformational freedom of the target compound whilst retaining desired chemical properties is...
Polymorphism of the azobenzene dye compound methyl yellow
Dyanne L. Cruickshank, Christopher H. Hendon, Matthew J R Verbeek, Aron Walsh, Chick C. Wilson
May 21, 2016
The crystal structure and polymorphism of the well-known aminoazobenzene, N,N-dimethyl-4-aminoazobenzene (DAB) are studied; a second polymorph of DAB reported and the relationship between the two polymorphs studied using...
Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors.
Matthew D Young, Thomas J Mitchell, Felipe A Vieira Braga, Maxine GB Tran, Benjamin J Stewart, John R Ferdinand, Grace Collord, Rachel A Botting, Dorin-Mirel Popescu, Kevin W Loudon, Roser Vento-Tormo, Emily Stephenson, Alex Cagan, Sarah J Farndon, Martin Del Castillo Velasco-Herrera, Charlotte Guzzo, Nathan Richoz, Lira Mamanova, Tevita Aho, James N Armitage, Antony CP Riddick, Imran Mushtaq, Stephen Farrell, Dyanne Rampling, James Nicholson, Andrew Filby, Johanna Burge, Steven Lisgo, Patrick H Maxwell, Susan Lindsay, Anne Y Warren, Grant D Stewart, Neil Sebire, Nicholas Coleman, Muzlifah Haniffa, Sarah A Teichmann, Menna Clatworthy, Sam Behjati
Nov 13, 2018
Messenger RNA encodes cellular function and phenotype. In the context of human cancer, it defines the identities of malignant cells and the diversity of tumor tissue. We studied 72,501 single-cell transcriptomes of human renal...
Polymorphism of the azobenzene dye compound methyl yellow
Dyanne L. Cruickshank, Christopher H. Hendon, Matthew J R Verbeek, Aron Walsh, Chick C. Wilson
May 21, 2016
The crystal structure and polymorphism of the well-known aminoazobenzene, N,N-dimethyl-4-aminoazobenzene (DAB) are studied; a second polymorph of DAB reported and the relationship between the two polymorphs studied using...
Single cell derived mRNA signals across human kidney tumors.
Matthew D Young, Thomas J Mitchell, Lars Custers, Thanasis Margaritis, Francisco Morales-Rodriguez, Kwasi Kwakwa, Eleonora Khabirova, Gerda Kildisiute, Thomas R W Oliver, Ronald R de Krijger, Marry M van den Heuvel-Eibrink, Federico Comitani, Alice Piapi, Eva Bugallo-Blanco, Christine Thevanesan, Christina Burke, Elena Prigmore, Kirsty Ambridge, Kenny Roberts, Felipe A Vieira Braga, Tim H H Coorens, Ignacio Del Valle, Anna Wilbrey-Clark, Lira Mamanova, Grant D Stewart, Vincent J Gnanapragasam, Dyanne Rampling, Neil Sebire, Nicholas Coleman, Liz Hook, Anne Warren, Muzlifah Haniffa, Marcel Kool, Stefan M Pfister, John C Achermann, Xiaoling He, Roger A Barker, Adam Shlien, Omer A Bayraktar, Sarah A Teichmann, Frank C Holstege, Kerstin B Meyer, Jarno Drost, Karin Straathof, Sam Behjati
Jul 28, 2021
Kidney Fetus Humans Kidney Neoplasms RNA Messenger Signal Transduction Gene Expression Regulation Developmental Algorithms Models Genetic Adult Child Single-Cell Analysis Transcriptome RNA-seq
Published by: Nature Communications
Spatiotemporal immune zonation of the human kidney.
Benjamin J Stewart, John R Ferdinand, Matthew D Young, Thomas J Mitchell, Kevin W Loudon, Alexandra M Riding, Nathan Richoz, Gordon L Frazer, Joy UL Staniforth, Felipe A Vieira Braga, Rachel A Botting, Dorin-Mirel Popescu, Roser Vento-Tormo, Emily Stephenson, Alex Cagan, Sarah J Farndon, Krzysztof Polanski, Mirjana Efremova, Kile Green, Martin Del Castillo Velasco-Herrera, Charlotte Guzzo, Grace Collord, Lira Mamanova, Tevita Aho, James N Armitage, Antony CP Riddick, Imran Mushtaq, Stephen Farrell, Dyanne Rampling, James Nicholson, Andrew Filby, Johanna Burge, Steven Lisgo, Susan Lindsay, Marc Bajenoff, Anne Y Warren, Grant D Stewart, Neil Sebire, Nicholas Coleman, Muzlifah Haniffa, Sarah A Teichmann, Sam Behjati, Menna R Clatworthy
Oct 07, 2019
Single cell derived mRNA signals across human kidney tumors.
Matthew D Young, Thomas J Mitchell, Lars Custers, Thanasis Margaritis, Francisco Morales-Rodriguez, Kwasi Kwakwa, Eleonora Khabirova, Gerda Kildisiute, Thomas RW Oliver, Ronald R de Krijger, Marry M van den Heuvel-Eibrink, Federico Comitani, Alice Piapi, Eva Bugallo-Blanco, Christine Thevanesan, Christina Burke, Elena Prigmore, Kirsty Ambridge, Kenny Roberts, Felipe A Vieira Braga, Tim HH Coorens, Ignacio Del Valle, Anna Wilbrey-Clark, Lira Mamanova, Grant D Stewart, Vincent J Gnanapragasam, Dyanne Rampling, Neil Sebire, Nicholas Coleman, Liz Hook, Anne Warren, Muzlifah Haniffa, Marcel Kool, Stefan M Pfister, John C Achermann, Xiaoling He, Roger A Barker, Adam Shlien, Omer A Bayraktar, Sarah A Teichmann, Frank C Holstege, Kerstin B Meyer, Jarno Drost, Karin Straathof, Sam Behjati
Mar 03, 2021
Tumor cells may share some patterns of gene expression with their cell of origin, providing clues into the differentiation state and origin of cancer. Here, we study the differentiation state and cellular origin of 1300...
How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis
Nick G Cunniffe, Simon J Gunter, Michael Brown, Sarah W Burge, Clare Coyle, Anthony De Soyza, Tom Dymond, Hanif Esmail, Darrel P Francis, Jacqui Galloway, James B Galloway, Effrossyni Gkrania-Klotsas, Jane Greenaway, George Katritsis, Prapa Kanagaratnam, Martin D Knolle, Kelly Leonard, Zoe C McIntyre, Ben Prudon, Tommy Rampling, Mili Estee Torok, Ben Warne, Mark Yates, Nicholas J Matheson, Li Su, Sofia Villar, Grant D Stewart, Mark Toshner
Oct 07, 2020
Objectives: To analyse enrolment to interventional trials during the first wave of the COVID-19 pandemic in England and describe the barriers to successful recruitment in the circumstance of a further wave or future pandemics....
How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis.
Nick G Cunniffe, Simon J Gunter, Michael Brown, Sarah W Burge, Clare Coyle, Anthony De Soyza, Tom Dymond, Hanif Esmail, Darrel P Francis, Jacqui Galloway, James B Galloway, Effrossyni Gkrania-Klotsas, Jane Greenaway, George Katritsis, Prapa Kanagaratnam, Martin D Knolle, Kelly Leonard, Zoe C McIntyre, Ben Prudon, Tommy Rampling, Mili Estee Torok, Ben Warne, Mark Yates, Nicholas J Matheson, Li Su, Sofia Villar, Grant D Stewart, Mark Toshner
Sep 24, 2020
covid-19 Clinical Trials Infectious Diseases Betacoronavirus Biomedical Research covid-19 Coronavirus Infections Eligibility Determination Female Health Services Accessibility Hospitalization Humans Male Middle Aged Pandemics Patient Selection Pneumonia Viral Prospective Studies Randomized Controlled Trials as Topic Registries SARS-CoV-2 United Kingdom
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST)
Alasdair PS Munro, Shuo Feng, Leila Janani, Victoria Cornelius, Parvinder K Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee, Kate Dodd, Yvanne Enever, Ehsaan Qureshi, Anna L Goodman, Christopher A Green, Linda Harndahl, John Haughney, Alexander Hicks, Agatha A van der Klaauw, Nasir Kanji, Vincenzo Libri, Martin J Llewelyn, Alastair C McGregor, Mina Maallah, Angela M Minassian, Patrick Moore, Mehmood Mughal, Yama F Mujadidi, Kyra Holliday, Orod Osanlou, Rostam Osanlou, Daniel R Owens, Mihaela Pacurar, Adrian Palfreeman, Daniel Pan, Tommy Rampling, Karen Regan, Stephen Saich, Tanveer Bawa, Dinesh Saralaya, Sunil Sharma, Ray Sheridan, Emma C Thomson, Shirley Todd, Chris Twelves, Robert C Read, Sue Charlton, Bassam Hallis, Mary Ramsay, Nick Andrews, Teresa Lambe, Jonathan S Nguyen-Van-Tam, Matthew D Snape, Xinxue Liu, Saul N Faust, COV-BOOST study group
Jun 13, 2022
BACKGROUND: Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the safety...
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK
Xinxue Liu, Alasdair PS Munro, Shuo Feng, Leila Janani, Parvinder K Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee, Wanwisa Dejnirattisai, Kate Dodd, Yvanne Enever, Ehsaan Qureshi, Anna L Goodman, Christopher A Green, Linda Harndahl, John Haughney, Alexander Hicks, Agatha A van der Klaauw, Jonathan Kwok, Vincenzo Libri, Martin J Llewelyn, Alastair C McGregor, Angela M Minassian, Patrick Moore, Mehmood Mughal, Yama F Mujadidi, Kyra Holliday, Orod Osanlou, Rostam Osanlou, Daniel R Owens, Mihaela Pacurar, Adrian Palfreeman, Daniel Pan, Tommy Rampling, Karen Regan, Stephen Saich, Teona Serafimova, Dinesh Saralaya, Gavin R Screaton, Sunil Sharma, Ray Sheridan, Ann Sturdy, Piyada Supasa, Emma C Thomson, Shirley Todd, Chris Twelves, Robert C Read, Sue Charlton, Bassam Hallis, Mary Ramsay, Nick Andrews, Teresa Lambe, Jonathan S Nguyen-Van-Tam, Victoria Cornelius, Matthew D Snape, Saul N Faust, COV-BOOST study group
May 13, 2022
OBJECTIVES: To evaluate the persistence of immunogenicity three months after third dose boosters. METHODS: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster...
COVID-19 vaccine Fractional dose Heterologous boost Homologous boost Immunogenicity Persistence Third dose Ad26COVS1 Adult Aged Aged 80 and over Antibodies Viral BNT162 Vaccine covid-19 COVID-19 Vaccines ChAdOx1 nCoV-19 Humans Immunogenicity Vaccine Immunoglobulin G Middle Aged SARS-CoV-2 United Kingdom Viral Vaccines mRNA Vaccines